Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study by Nash, P, Coates, LC, Fleishaker, D, Kivitz, AJ, Mease, PJ, Gladman, DD, FitzGerald, O, Wang, C, Wu, J, Hsu, M-A, Menon, S, Fallon, L, Kanik, KS

Safety and efficacy of Tofacitnib in patients with active psoriatic arthritis: Interim analysis of OPAL balance, an open-label, long-term extension study by Nash, P, Coates, LC, Kivitz, AJ, Mease, PJ, Gladman, DD, Covarrubias-Cobos, JA, FitzGerald, O, Fleishaker, D, Wang, C, Wu, J, Hsu, M-A, Menon, S, Fallon, L, Romero, AB, Kanik, KS